Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) or its ligand (PD-L1) have achieved significant improvements in clinical adjuvant therapy for esophageal/esophagogastric junction carcinoma (8), bladder cancer (9), melanoma (10), and lung cancer (11). Here, PDCD1 is linked to lung cancer.